Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Syneron Medical Ltd.    ELOS   IL0010909351

SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisionsForum 
Income Statement Evolution
Syneron Medical Ltd. : Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 201020112012201320142015
Sales190228264290323356
Operating income (EBITDA)-24,2-35,314,436,147,2-
Operating profit (EBIT)-33,4-45,711,222,639,048,0
Pre-Tax Profit (EBT)---6,84---
Net income-25,5-47,6-1,344,1818,539,1
EPS ( $)-0,74-1,35-0,040,120,511,07
Dividend per Share ( $)------
Yield------
Announcement Date02/16/2011
12:00pm
02/09/2012
12:30pm
02/12/2013
12:44pm
---
Finances - Leverage
Syneron Medical Ltd. : Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 201020112012201320142015
Debt------
Finance------
Operating income (EBITDA)-24,2-35,314,436,147,2-
Leverage
(Debt/EBITDA)
------
Capital Expenditure0,892,122,092,472,602,80
Book Value Per Share (BVPS)7,99 $6,61 $----
Cash Flow per Share------
Announcement Date02/16/2011
12:00pm
02/09/2012
12:30pm
02/12/2013
12:44pm
---
Assessed data source :
© 2013 Thomson Reuters
Advertisement
Financial Ratios

Size 2013e 2014e
Capitalization 317 M$ -
Company Value - 317 M$
Valuation 2013e 2014e
PER (Price / EPS) 77,5x 17,5x
Capitalization / Revenue 1,09x 0,98x
EV / Revenue - -
EV / EBITDA - -
Yield (DPS / Price) - -
Profitability 2013e 2014e
Operating Margin (EBIT / Sales) 7,79% 12,1%
operating laverage (Delta EBIT / Delta Sales) 10,2x 6,37x
Net Margin (Net Profit / Revenue) 1,44% 5,73%
ROA (Net Profit / Asset) - -
ROE (Net Profit / Equities) - -
Rate of Dividend - -
Balance Sheet Analysis 2013e 2014e
CAPEX / Sales   0,85% 0,80%
Cash Flow / Sales (Taux d'autofinancement) - -
Capital Intensity (Assets / Sales) - -
Financial Leverage (Net Debt / EBITDA) - -
Price Earning Ratio
Syneron Medical Ltd. : Price Earning Ratio
EPS & Dividend
Syneron Medical Ltd. : EPS Dividend
Dynamic quotes  
ON
| OFF
Copyright © 2013 Surperformance. All rights reserved.